CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Hemoglobin decline above 2g/dl during Peginterferon alfa-2b (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR in patients with HCV genotype 1 and HCV genotype 2/3 infection without erythropoietin use
DOI 10.1055/s-0032-1332182
Bibliografische Angaben
Nachweis in CareLit
Autor:innenG Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, A Heuser, M Bilzer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: It has been shown that anemia and the hemoglobin (Hb) decline during Peg2b/RBV treatment of genotype 1 (G1) infection predict favorable SVR rates (Sulkowski M, Gastroenterology 2010). However, approximately 50% of the patients with anemia received erythropoietin, which may have confounded the association between Hb decline and SVR. We here investigated whether the association between Hb decline and SVR c…
Zitieren
Zitierempfehlung
G Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, A Heuser, M Bilzer (2013) Hemoglobin decline above 2g/dl during Peginterferon alfa-2b (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR in patients with HCV genotype 1 and HCV genotype 2/3 infection without erythropoietin use. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0032-1332182
Mit CareLit weiterarbeiten